


Clonal hematopoiesis after autologous stem cell transplantation does not confer adverse prognosis in patients with AML following autologous stem cell transplantation

Supplemental Material

Figure S1: Distribution of mutations and variant allele frequencies (VAFs). **A:** Absolute numbers of CH-mutations in *DNMT3A*, *TET2* and *ASXL1* detected at diagnosis and during complete remission in the absence of leukemia-related mutations. **B:** Variant allele frequencies of CH-related mutations in *DNMT3A*, *TET2* and *ASXL1* observed during complete remission. Grey dashes indicate medians.



A Progression free survival

Percent survival

Months

$P = .157$

Number at risk

Months	0	24	48	72	96	120	144	168	192
no CH	79	33	20	11	6	4	1	1	1
DNMT3A-CH	24	11	8	7	5	4	3	2	2

1 — no CH
2 — DNMT3A-CH

B Overall survival

Percent survival

Months

$P = .339$

Number at risk

Months	0	24	48	72	96	120	144	168	192
no CH	79	43	25	12	6	4	1	1	1
DNMT3A-CH	24	14	11	9	6	5	3	2	2

1 — no CH
2 — DNMT3A-CH

C Progression free survival

Percent survival

Months

$P = .909$

Number at risk

Months	0	24	48	72	96	120	144	168	192
no CH	79	33	20	11	6	4	1	1	1
TET2-CH	7	4	3	3	2	2	1	1	1

1 — no CH
1 — TET2-CH

D Overall survival

Percent survival

Months

$P = .641$

Number at risk

Months	0	24	48	72	96	120	144	168	192
no CH	79	43	25	12	6	4	1	1	1
TET2-CH	7	4	4	4	4	3	1	1	1

1 — no CH
1 — TET2-CH

E Progression free survival

Percent survival

Months

$P = .203$

Number at risk

Months	0	24	48	72	96	120	144	168	192
no CH	79	33	20	11	6	4	1	1	1
ASXL1-CH	4	4	3	3	2	2	1	1	1

1 — no CH
1 — ASXL1-CH

F Overall survival

Percent survival

Months

$P = .338$

Number at risk

Months	0	24	48	72	96	120	144	168	192
no CH	79	43	25	12	6	4	1	1	1
ASXL1-CH	4	4	3	3	2	2	1	1	1

1 — no CH
1 — ASXL1-CH

G Progression free survival

Percent survival

Months

$P = .721$

Number at risk

Months	0	24	48	72	96	120	144	168	192
no CH	79	33	20	11	6	4	1	1	1
non-DNMT3A-CH	7	6	3	3	2	2	1	1	1

1 — no CH
1 — non-DNMT3A-CH

H Overall survival

Percent survival

Months

$P = .440$

Number at risk

Months	0	24	48	72	96	120	144	168	192
no CH	79	43	25	12	6	4	1	1	1
non-DNMT3A-CH	7	5	3	3	2	2	1	1	1

1 — no CH
1 — non-DNMT3A-CH

Figure S3: Survival according to different VAF (variant allele frequencies) cutoffs. Kaplan-Meier survival estimates of patients with and without CH determined at different VAF (variant allele frequency) cutoffs. **A-B:** Cutoff at 5% VAF. **C-D:** Cutoff at 10% VAF.

